REG - Roquefort Theraptcs. - Appointment of Broker

Roquefort TherapeuticsAnnouncement

20/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240620:nRST1220Ta&default-theme=true

RNS Number : 1220T  Roquefort Therapeutics PLC  20 June 2024

20 June 2024

 

Roquefort Therapeutics plc

("Roquefort Therapeutics")

Appointment of Broker

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech
company focused on developing first in class medicines in the high value and
high growth immuno-oncology market, is pleased to announce the appointment of
SP Angel Corporate Finance LLP as its broker with immediate effect.

-ENDS-

Enquiries:

 Roquefort Therapeutics plc                       +44 (0)20 3918 8633
 Stephen West (Chairman) / Ajan Reginald (CEO)
 SP Angel Corporate Finance LLP (Broker)          +44 (0) 20 3470 0470

 Jeff Keating / David Hignell / Vadim Alexandre

 Buchanan (Public Relations)                      +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper / George Beale

 Peak IR (Investor Relations)                     +33 (0)7 44 44 15 42

 Seb Wykeham

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech
company developing first in class drugs in the high value and high growth
immuno-oncology segment prior to partnering or selling to big pharma.

 

Roquefort Therapeutics' portfolio consists of five novel, patent-protected
pre-clinical anti-cancer medicines.  The highly complementary profile of five
best-in-class medicines consists of:

·   Midkine antibodies with significant in vivo efficacy and toxicology
studies;

·   Midkine RNA therapeutics with novel anti-cancer gene editing action;

·   Midkine mRNA therapeutics with novel anti-cancer approach;

·   STAT-6 siRNA therapeutics targeting solid tumours with significant in
vivo efficacy; and

·   MK cell therapy with direct and NK-mediated anti-cancer action

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)
 and @RoquefortTherap on X (formerly Twitter).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPUKUNRSWUNAAR